Piramal Pharma Ltd. (PPLPHARMA): Piramal Pharma Share Price Falls 3.62% as Stock Turns Top Decliner

Piramal Pharma slipped to Rs 204.75, down 3.62% today, with market capitalisation at Rs 28,004.91 crore as the stock featured among notable large-cap decliners.

Piramal Pharma Share Price fell to Rs 204.75 on 14 August 2026, a decline of 3.62% from the previous close of Rs 212.45, bringing the company’s market capitalisation to Rs 28,004.91 crore. That move placed the stock firmly on the radar in Stock Market Today and made it relevant not simply because it declined, but because the fall was large enough for a Large Cap name to trigger the event threshold tracked by Univest.

The session data shows a volatile day rather than a one-way collapse. The stock opened at Rs 203.70, moved as high as Rs 215.80 and touched a low of Rs 202.30 before trading at Rs 204.75. Total traded volume stood at 1,03,30,348 shares across exchanges, including NSE volume of 93,16,718 shares and BSE volume of 10,13,630 shares, while turnover was Rs 20.75 crore on the exchange volume source used for the event. In practical terms, Piramal Pharma Share Price Today became part of the Top Losers Today list even though the day’s range shows active intraday participation on both sides.

The supplied data confirms the price fall and elevated trading activity, but it does not establish a company-specific catalyst behind why the stock is falling. That is why the more useful approach is to study the price action, trading participation, sector context and peer positioning. In this Univest stock analysis, the focus stays on verified numbers, what they say about Piramal Pharma Stock News today, and what investors may want to monitor next without turning the move into a prediction.

Piramal Pharma Ltd. (PPLPHARMA) Share Price Today: Price Action Analysis

Piramal Pharma Ltd. (PPLPHARMA) traded at Rs 204.75. versus the previous close of Rs 212.45, a fall of 3.62%. The stock opened at Rs 203.7, reached Rs 215.8, touched Rs 202.3. Reported volume was 10,13,630.

Piramal Pharma Ltd. (PPLPHARMA) Fundamental Analysis

Piramal Pharma Fundamental Analysis is constrained to the numbers directly supplied, but even that set offers context. The most important verified company metric available today is market capitalisation of Rs 28,004.91 crore. Market cap does not indicate quality by itself, yet it does show that Piramal Pharma is materially larger than many listed companies in the same healthcare benchmark universe used here.

That size can matter for how the market reads a single-day fall. A 3.62% decline in a stock with a market value of Rs 28,004.91 crore is different from a similar move in a much smaller counter because it reflects price repositioning in a far larger equity base. In Piramal Pharma Share Price Today, the fall therefore carries weight as a large-cap event rather than as a minor fluctuation in a thinly traded name.

The day’s turnover of Rs 20.75 crore and total volume of 1,03,30,348 shares add another layer to the financial analysis. These figures indicate that the move was accompanied by meaningful activity rather than a negligible trade sample. For investors following Piramal Pharma Share Price Fall, the key takeaway is not that the data proves a lasting trend, but that the market clearly repriced the stock during the session.

Because the supplied company fundamentals do not include valuation multiples such as P/E Ratio, P/B Ratio or EV/EBITDA, nor profitability ratios such as ROE and ROCE, the present Piramal Pharma Stock Analysis has to rely more heavily on size, trading behaviour and external sector benchmarks. That still helps frame investor attention. A large-cap healthcare company seeing this level of intraday range, volume and closing decline naturally becomes part of Stocks in News and Piramal Pharma Latest News searches. From a Univest perspective, the next useful lens is ownership structure where available and, in this case, especially the broader healthcare sector benchmark.

Sector and Industry Context

Piramal Pharma Ltd. (PPLPHARMA) is classified under sector: Healthcare.

Track today’s top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.

The healthcare benchmark provides useful perspective for this price fall because it shows how broad the valuation and profitability spread is across the comparison set. Piramal Pharma is being assessed against a same-sector universe of 196 companies, which helps place today’s move in a wider Industry Analysis framework.

Within this Healthcare benchmark, 156 companies had available P/E data. The median P/E was 26.20, while the average was 75.33, with an unusually wide range from 3.29 to 3,299.57. That dispersion suggests the sector contains both relatively mature businesses and highly stretched valuation outliers. For price discovery, that is important: sector-level multiples alone can be misleading if the spread is this broad.

On price-to-book, 195 companies were available, with a median of 1.96 and an average of 2.65. The range ran from -10.01 to 16.63. Profitability also showed variation. Median ROE stood at 11.07% against an average of 15.46%, while median ROCE was 13.35% and average ROCE was 17.73% across 195 companies each. These numbers indicate a healthcare universe where performance quality differs sharply from one business to another.

Market capitalisation data is equally striking. Across 196 companies, the median market cap was Rs 141.55 crore and the average was Rs 465.17 crore, with a range from Rs 3.67 crore to Rs 2,995.34 crore in the benchmark table supplied. Against that, Piramal Pharma Market Cap of Rs 28,004.91 crore stands out as substantially larger than the benchmark company range shown here. That does not make the stock stronger or weaker on its own, but it does underline why Piramal Pharma Share Price Today attracted attention as a large-cap move inside a sector where most listed comparables in the snapshot are far smaller. Univest reads this as a meaningful relative-size signal within the Healthcare segment.

Peer Comparison

Piramal Pharma Ltd. (PPLPHARMA) has a market capitalisation of Rs 28,004.91 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

The supplied peer set shows a healthcare group with wide differences in valuation, profitability and scale. Piramal Pharma’s most obvious distinguishing feature versus these peers is sheer size: its market capitalisation of Rs 28,004.91 crore is far above every peer listed in the snapshot.

The largest peer in the supplied comparison is Dishman Carbogen Amcis Ltd. at Rs 2,995.34 crore, followed by Beta Drugs Ltd. at Rs 2,836.87 crore and Dr Agarwals Eye Hospital Ltd. at Rs 2,644.55 crore. Hikal Ltd. stands at Rs 2,619.52 crore, while Ind-Swift Laboratories Ltd. is at Rs 2,605.37 crore. Even the remaining names such as Panacea Biotec Ltd. at Rs 2,450.34 crore, Sai Parenteral’s Ltd. at Rs 2,441.79 crore, Solara Active Pharma Sciences Ltd. at Rs 2,436.78 crore, Fredun Pharmaceuticals Ltd. at Rs 2,304.91 crore and Venus Remedies Ltd. at Rs 2,214.91 crore are far below Piramal Pharma on market value.

Valuation and profitability across peers are mixed. Dishman trades at 31.94 times earnings with P/B of 0.47, but its ROE is -2.89% and ROCE is -0.26%. Beta Drugs carries a much richer P/E of 69.35 and P/B of 10.97, supported by ROE of 18.65% and ROCE of 22.17%. Dr Agarwals shows P/E of 34.70 and P/B of 7.15, but ROE is -2.60% despite ROCE of 16.92%. Hikal has P/B of 2.24 with ROE of 15.22% and ROCE of 16.15%, though no P/E is supplied in this dataset.

Among smaller peers, Ind-Swift Laboratories is on 45.02 times earnings with P/B of 1.73, while Sai Parenteral’s trades at 174.73 times earnings and P/B of 3.19. Fredun Pharmaceuticals is at 56.53 times earnings and P/B of 8.44, whereas Venus Remedies is on 19.99 times earnings and P/B of 3.38. Since company-specific P/E, P/B, ROE and ROCE for Piramal Pharma are not part of the supplied data, the clean conclusion is limited but still useful: Piramal Pharma Share Price sits in a much larger market-cap bracket than the peers shown, while the peer group itself spans both profitable and weak-return businesses across healthcare and pharmaceuticals. That is valuable context for Piramal Pharma Stock News and Peer Comparison searches on Univest.

Why Investors Are Watching Piramal Pharma

Piramal Pharma Share Price is being watched because the stock recorded a verified large-cap price fall of 3.62% in a session that also showed a broad intraday range and strong market participation. In Market Update terms, this was not just a routine tick lower. The move pushed the stock into the top decliner conversation, while the lack of a confirmed company-specific catalyst means the market is currently responding more to price behaviour than to any verified corporate trigger in the supplied data.

• Verified price move: The stock fell Rs 7.70 from Rs 212.45 to Rs 204.75.
• Intraday volatility: The session ranged from Rs 202.30 to Rs 215.80 after opening at Rs 203.70.
• Trading participation: Total volume was 1,03,30,348 shares, including 93,16,718 on NSE and 10,13,630 on BSE.
• Large-cap relevance: Market capitalisation remains Rs 28,004.91 crore, making the move notable in a bigger stock.
• Sector context: Healthcare benchmark valuations and returns are widely dispersed, keeping relative positioning important.
• Peer backdrop: The supplied peers are much smaller, with varied P/E, P/B, ROE and ROCE profiles.

What investors may monitor next is whether Piramal Pharma Share Price stabilises near the lower end of today’s band or remains under Selling Pressure in coming sessions. The most relevant verified markers for now are the closing price relative to the day low of Rs 202.30, continued Trading Volume, and whether the stock continues to feature among Stocks Under Pressure rather than participating in today’s rally elsewhere in the Indian Stock Market.

About Piramal Pharma

Piramal Pharma Ltd. is a listed Indian healthcare company tracked on both NSE and BSE under the symbol PPLPHARMA in the supplied market data. The verified classification available here places the company in the Healthcare sector, which is enough to situate it within one of the major defensive and research-intensive segments of the Indian Stock Market.

In the context of this article, the most important aspect of the company profile is its scale. With a market capitalisation of Rs 28,004.91 crore, Piramal Pharma is far larger than the healthcare benchmark companies and peers shown in the supplied dataset. That does not define business quality, but it does indicate that the market treats the stock as a meaningful sector constituent rather than as a niche micro-cap or thinly followed counter.

The peer list linked to the same sector includes pharmaceutical and healthcare service companies such as Dishman Carbogen Amcis, Beta Drugs, Dr Agarwals Eye Hospital, Hikal, Ind-Swift Laboratories, Panacea Biotec, Sai Parenteral’s, Solara Active Pharma Sciences, Fredun Pharmaceuticals and Venus Remedies. That comparison set shows how broad the healthcare investment universe is, spanning different valuation and profitability profiles.

For readers tracking Piramal Pharma Company News or Piramal Pharma Share News, the immediate takeaway is straightforward: this is a large healthcare stock whose share price decline has become relevant because of the size of the move, the size of the company and the level of trading activity recorded during the session. Univest will continue to frame Piramal Pharma Share Price within that sector and market context.

Track Piramal Pharma Share Price on Univest

Use Piramal Pharma Ltd. (PPLPHARMA) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.

Investors who want to follow Piramal Pharma Share Price more closely can use Univest to track live price movement, day change, market capitalisation and broader stock analysis in one place. For active market participants, Piramal Pharma Share Price Today becomes more useful when viewed alongside exchange-wise volume, intraday range and how the stock is behaving relative to other market movers.

Univest also helps users monitor key market insights around Piramal Pharma Stock News, 52-week levels, shareholding pattern when available, sector positioning and peer comparison. That combination is particularly relevant after a session like this, where Piramal Pharma Share Price Fall has pushed the stock into focus. Rather than relying on headlines alone, investors can use Univest to keep track of verified price data, contextual ratios and ongoing stock updates without turning short-term movement into a recommendation.

Frequently Asked Questions

Why did Piramal Pharma Share Price fall today?

Ans. Piramal Pharma Share Price fell 3.62% to Rs 204.75 from the previous close of Rs 212.45. The supplied data confirms the price fall and strong trading activity, but it does not identify any verified company-specific catalyst for the decline.

What was Piramal Pharma Share Price Today on 14 August 2026?

Ans. Piramal Pharma Share Price Today was Rs 204.75 at the time of the event capture on 14 August 2026. The stock was down Rs 7.70 for the day, equivalent to a 3.62% share price decline from Rs 212.45.

What were the day high and day low for Piramal Pharma shares?

Ans. Piramal Pharma traded between a day high of Rs 215.80 and a day low of Rs 202.30. That broad intraday band shows active price movement, with the stock finally settling closer to the lower end of the session range.

How much volume was traded in Piramal Pharma today?

Ans. Total traded volume in Piramal Pharma stood at 1,03,30,348 shares. This included 93,16,718 shares on NSE and 10,13,630 shares on BSE, showing that the stock’s share price decline came with meaningful market participation.

What was the turnover recorded for Piramal Pharma in this session?

Ans. The supplied session turnover for Piramal Pharma was Rs 20.75 crore. Along with a 3.62% fall and total volume above one crore shares, that turnover figure underlines why the stock became a notable market mover today.

Is Piramal Pharma a large-cap stock?

Ans. Yes, Piramal Pharma is classified as a Large Cap stock in the supplied dataset. Its market capitalisation was Rs 28,004.91 crore, which is why today’s 3.62% decline was screened as a significant large-cap price fall event.

Why is Piramal Pharma among top losers today?

Ans. Piramal Pharma featured among Top Losers Today because the stock declined 3.62% in a single session. The move was large enough for its market-cap category and was accompanied by total traded volume of 1,03,30,348 shares.

How does Piramal Pharma compare with the healthcare sector by size?

Ans. Piramal Pharma’s market capitalisation of Rs 28,004.91 crore is far above the healthcare benchmark snapshot, where the median market cap was Rs 141.55 crore and the average was Rs 465.17 crore across 196 companies.

What does the healthcare sector benchmark show right now?

Ans. In the supplied healthcare benchmark, median P/E was 26.20 and average P/E was 75.33 across 156 companies. Median ROE was 11.07% and median ROCE was 13.35%, showing a wide spread in sector quality and valuation.

Which peers are included in the Piramal Pharma comparison set?

Ans. The supplied peer set includes Dishman Carbogen Amcis, Beta Drugs, Dr Agarwals Eye Hospital, Hikal, Ind-Swift Laboratories, Panacea Biotec, Sai Parenteral's, Solara Active Pharma Sciences, Fredun Pharmaceuticals and Venus Remedies from the healthcare universe.